ERBB2 and gastroesophageal junction adenocarcinoma: Disitamab vedotin has been approved in China for patients with HER2‐positive gastric cancer or gastroesophageal junction adenocarcinoma who have undergone two or more chemotherapy regimens based on several clinical trials.100, 125, 126, 127